Clinical Trial Update: Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tolerability and safety of subcutaneous AFFITOPE AD02 in individuals with mild to moderate Alzheimer's disease; the trial has been comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AFFITOPE AD02 (AD02)

Snippet

Sponsor: Affiris AG | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED